Potential of Xeloda® in colorectal cancer and other solid tumors

Oncology

Volumn 57, Issue SUPPL. 1, 1999, Pages 27-32

  Cassidy, Jim ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

5 FU; Colorectal cancer; Fluoropyrimidines; Leucovorin; Phase I; Solid tumors; Tumor selective activation; Xeloda (capecitabine)

Indexed keywords

CAMPTOTHECIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; HEALTH CARE UTILIZATION; HUMAN; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; SOLID TUMOR; VOMITING; COLORECTAL TUMOR; METABOLISM; NEOPLASM; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NEOPLASMS;

EID: 0033161229     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055266     Document Type: Article

References (26)

1. Meropol NJ: Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 1998;34:1509-1513.
2. Bleiberg H: Colorectal cancer: The challenge. Eur J Cancer 1996;32A(suppl 5):S2-S6.
3. Cohen AM, Minsky BD, Schilsky RL: Cancer of the colon; in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 1144-1195.
4. Pinedo HM, Peters GFJ: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
5. Allegra CJ, Grem JL: Antimetabolites; in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 432-452.
6. Liu G, Franssen E, Fitch M, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
7. Payne SA: A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992;35:1505-1509.
8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
9. Schüller J, Cassidy J, Reigner BG, Roos B, Pietrzak C, Springer B, Ishitsuka H, Utoh M, Dumont E: Tumor selectivitiy activation of Capecitabine in colorectal cancer patients. Onkologie 1997;20 suppl 1 (abstract 732).
10. Kovach JS, Beart RW Jr: Cellular pharmacology of fluorinated pyrimidines in vivo in man. Invest New Drugs 1989;7:13-25.
11. Danenberg K, Metzger R, Groshen S, Schwartz EL, Wadler S, Danenberg P, Leichman C: Thymidylate synthase and thymidine phosphorylase are prognostic indicators of survival for colorectal cancer. Proc Am Soc Clin Oncol 1997;16:257a (abstract 914).
12. Toi M, Ohashi T, Takatsuka Y, Shin E, Inaji H, Yamamoto Y, Tominaga T: Selective effect of adjuvant 5′-deoxy-5-fluorouridine treatment for thymidine phosphorylase positive tumors in primary breast cancer. Proc Am Soc Clin Oncol 1997;16:136a (abstract 481).
13. Maeda K, Chung Y-S, Ogawa S, Takatsuka S, Kang SM, Ogawa M, Sawada T, Onoda N, Kato Y, Sowa M: Thymidine phosphorylase/ platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996;73: 884-888.
14. Takebayashi Y, Akiyama S, Akiba K, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T: Clinicopathological and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996;88:1110-1117.
15. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T, Aikou T: Expression of thymidine phosphorylase, in human gastric carcinoma. Jpn J Cancer Res 1996;87:288-295.
16. Mizutani Y, Okada Y, Yoshida O: Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79: 1190-1194.
17. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, Moghaddam A, Harris AL, Bicknell R: Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994;86:1234-1238.
18. Imazono Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S, Ohi Y: Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997;15:2570-2578.
19. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
20. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977-2985.
21. Budman DR, Meropal NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16: 1795-1802.
22. Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B, Van Oosterom AT: A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumours. Clin Cancer Res 1998;4:2755-2761.
23. Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Padzur R, Verweij J: A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997;16:227a (abstract 798).
24. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
25. Khoury P, Villanona-Calero M, Blum J, Diab S, Elledge R, Kraynak M, Moczygemba J, Kromelis P, Morales I, Brown C, Griffin T, von Hoff D, Rowinsky E: Phase I study of capecitabine in combination with paclitaxel in patients with previously treated breast cancer. Proc Am Soc Clin Oncol 1998;15:206a (abstract 793).
26. Pronk I, Vasey PA, Sparreboom A, Gordon RJ, Reigner B, Osterwalder B, Verweij J, Twelves C: A matrix-designed phase I dose-finding and pharmacokinetic study of the combination of Xeloda™ plus Taxotere™. Proc Am Soc Clin Oncol 1998;17:212a (abstract 816).